TY - JOUR
T1 - Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation
AU - Kansagra, A.
AU - Inwards, D. J.
AU - Ansell, S. M.
AU - Micallef, I. N.
AU - Johnston, P. B.
AU - Hogan, W. J.
AU - Markovic, S. N.
AU - Porrata, L. F.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.
AB - The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.
UR - http://www.scopus.com/inward/record.url?scp=85041545981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041545981&partnerID=8YFLogxK
U2 - 10.1038/bmt.2017.225
DO - 10.1038/bmt.2017.225
M3 - Article
C2 - 29035394
AN - SCOPUS:85041545981
SN - 0268-3369
VL - 53
SP - 146
EP - 154
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 2
ER -